Literature DB >> 22005901

Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Nageshwar R Budha1, Andreas Kovar, Bernd Meibohm.   

Abstract

Prolonged time delay in response to drug action is a common feature of hematological responses to pharmacotherapy such as erythropoiesis. The objective of this study was to compare the performance of two competing modeling approaches for delayed drug effects, mechanistic cell life span models, and semi-mechanistic cell transit models. The comparison was performed with an experimental dataset from multiple dose administrations of an erythropoietin mimetic to Cynomolgus monkeys. Comparative performance measures include visual predictive checks, goodness-of-fit plots, model estimation time, estimation status, and estimation error. The analysis revealed that both models resulted in a similarly good description of the erythropoietic drug effect, with precision and bias of the model-based predictions of red blood cell counts of less than 11%. The cell transit model needed slightly longer time to converge compared to the cell life span model. The system and drug effect parameters were similar in both models indicating that the models can be interchangeably used to describe the current data. Thus, model selection would be dependent on the purpose of the modeling exercise, the available data, and the time allocated for model development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005901      PMCID: PMC3231865          DOI: 10.1208/s12248-011-9302-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  35 in total

1.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

Authors:  L A Harker; L K Roskos; U M Marzec; R A Carter; J K Cherry; B Sundell; E N Cheung; D Terry; W Sheridan
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Francis Farrell; Linda Joffee; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

3.  Population cell life span models for effects of drugs following indirect mechanisms of action.

Authors:  Juan J Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

4.  Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

Authors:  Lorin K Roskos; Peggy Lum; Pamela Lockbaum; Gisela Schwab; Bing-Bing Yang
Journal:  J Clin Pharmacol       Date:  2006-07       Impact factor: 3.126

5.  Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Authors:  Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-25       Impact factor: 2.745

6.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

7.  A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.

Authors:  M O Karlsson; V Molnar; J Bergh; A Freijs; R Larsson
Journal:  Clin Pharmacol Ther       Date:  1998-01       Impact factor: 6.875

8.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

9.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Authors:  L E Friberg; A Freijs; M Sandström; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

10.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

View more
  6 in total

1.  General relationship between transit compartments and lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-23       Impact factor: 2.745

Review 2.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 4.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

Review 5.  Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.

Authors:  Kyoung Ah Min; Xinyuan Zhang; Jing-yu Yu; Gus R Rosania
Journal:  Biopharm Drug Dispos       Date:  2013-12-10       Impact factor: 1.627

6.  Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.

Authors:  Gary Mo; Frank Gibbons; Patricia Schroeder; Wojciech Krzyzanski
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.